Cargando…
FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)
Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outc...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561766/ http://dx.doi.org/10.1002/advs.202270183 |